Present treatment and future expectations in advanced pancreatic cancer.

摘要: Advanced or metastatic pancreatic cancer is an incurable disease. The main treatment chemotherapy with cytotoxic agents. On the basis of our experience in clinical trials, objectives have been to determine response rate, life prolongation and benefit. In trials those other authors, all these met. Responses remain low; 5-25% patients a partial response, significantly achieved versus best supportive care, benefit observed 40-60% patients. Rarely do survive for over 2 years no patient cured. standard agent gemcitabine. addition agents, such as cisplatin, irinotecan, oxaliplatin taxanes, combination gemcitabine, has shown higher rates but overall survival not increased. Research related monoclonal gene therapies created hope. horizon broadened by recent report on tyrosine kinase inhibitor, erlotinib (EGFR inhibitor) which longer median survival, when combined gemcitabine alone. Other anti-angiogenic cetuximab anti-Her-2, herceptin, are now being tested ongoing trials. Farnesyl transferase inhibitors represent another direction research taking; this Ras-oncogenes (K-, H- N-ras) known be involved signal transduction pathways regulating cell growth differentiation many human cancers including pancreatic. Trials targeting produced expected effectiveness. and/or agents suggests there hope future.